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HISTORICAL PERSPECTIVE 
Liver disease and jaundice have been known and 
described since antiquity. The first written evidence 
that jaundice was recognized as infectious was in the 
eighth century in a letter from Pope Zecharias to St 
Boniface, and epidemics of jaundice have long been 
associated with war, famine and other catastrophic 
events. The first unmistakable outbreak of blood- 
borne viral hepatitis was recorded in 1885 among 
personnel of a Bremen shipyard who had been 
vaccinated against smallpox using human lymph; the 
vaccine was implicated as the cause of the epidemic. 
Despite this elegant piece of work and the evidence of 
other epidemiologic studies during the latter part of the 
nineteenth century and the first decades of this, it was 
generally believed that jaundice, commonly called 
catarrhal jaundice, was caused by an obstruction of the 
common bile duct with a mucus plug. A few lone 
voices, such as MacDonald in 1908, postulated a viral 
etiology for the disease, but the conventional view of 
acute hepatitis as an obstructive disease was not 
seriously challenged until World War 11, when a 
number of classical studies in the UK and the USA 
using human volunteers established beyond doubt 
the viral and infectious nature of the disease and 
distinguished the two main routes of transmission, 
feco-oral and parenteral. 
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In the decades immediately following the war, 
considerable money and effort were spent in investi- 
gating the viral etiology of hepatitis, but none were 
successful in identifying a candidate agent in cell 
culture. Major advances in understanding the modes of 
transmission, incubation times, and duration of viremia 
and of viral shedding of the two types of viral hepatitis 
were made through studies in experimentally infected 
primates. Further human experiments in and observa- 
tions on mentally handicapped children, and residents 
in institutions where viral hepatitis was endemic, proved 
that what became known as hepatitis A and B viruses 
(HAV, HBV) were immunologically distinct and that a 
long-term carrier state existed for HBV. 
The breakthrough came in the early 1960s by pure 
chance; Blumberg and his coworkers discovered an 
antigen in the serum of an Australian aborigine that was 
later found to be the coat protein of HBV. Blumberg 
was interested in the genetic polymorphism of serum 
proteins and was studying the precipitin reactions 
between antibodies in the serum of multiply transfused 
patients and antigens in a panel of sera from different 
geographical regions by simple two-dimensional 
immunodiffusion. This ‘Australia antigen’ was not at 
first associated with hepatitis, but because of the 
frequency with which it was found in the serum of 
patients with acute leukemia, it was suggested that it 
might be of value in the early diagnosis of this disease. 
Sera from patients with Down’s syndrome were 
examined because of the high risk of leukemia in this 
group, and one such patient seroconverted to Australia 
antigen positive at  the same time as developing acute 
hepatitis. Thus was the link made between the presence 
of the antigen in serum and HBV. Subsequently, in 
1974, the virus of hepatitis A was discovered by 
Feinstone and coworkers and then identified as a 
picornavirus. Since then (see below) a series of other 
hepatitis viruses have been discovered. 
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THE HEPATITIS ALPHABET 
At the time of the discovery of HBV surface antigen 
(HBsAg), post-transfusion jaundice was the most 
serious complication of the use of blood and blood 
products. Viral hepatitis was also a growing problem in 
heniodialysis, with a case mortality between 6% and 
28%1, and in the early 1970s HBsAg screening of blood 
donors and staff and patients in hemodialysis units was 
introduced. These early screening tests for HBsAg were 
insensitive but the technological development of new 
assays was rapid and by the end of the decade highly 
sensitive coriiniercial inimunoassays were available at  
relatively low cost. In-house and commercial assays for 
the diagnosis of hepatitis A by detection of IgM 
antibody were developed at  this time, initially using 
fecal antigen from human cases or experimentally 
infected marmosets, but later using cell-culture antigen. 
Following the introduction of routine HBsAg screening 
of blood donors it rapidly became obvious that there 
was another type of parenteral hepatitis. The consensus 
of various studies was that 90% of all cases of post- 
transfixion jaundice arid ‘transaminitis’ were caused by 
this agent or agents [l], and in the USA the risk of‘non- 
A, non-B hepatitis’ (NANBH) following a transfusion 
was estimated to be between 7% and 12% [2]. 
Hepatitis delta virus (HIIV) was discovered in 1977 
by imnmnofluorescence studies on liver biopsies [3] .  
HDV is a defective virus which cannot replicate 
without the help of HBV. Infection occurs either as a 
simultaneous co-infection with HBV or by super- 
infection of a n  HBV carrier. However, intensive work 
over more than a decade using conventional irnmuno- 
logic or virus isolation methods failed to identify any 
other agent of parenteral NANBH until eventually 
hepatitic C virus (HCV) was identified by cloning viral 
nucleic acid fragments from serum and the develop- 
ment of immunoassays for antibodies to recombinant 
proteins derived from these fragments [4]. Serologic 
surveys have shown that HCV is responsible for the 
majority of cases of post-transfusion NANBH and 
is implicated in some cases of comniunity-acquired 
sporadic hepatitis [5,6]. Acute epidemic hepatitis in 
Table 1 A provisional listing of hepatitis viruscs 
adults associated with the consumption of sewage- 
contaminated food or water is common in India and 
Africa, and it had been assumed that this was hepatitis 
A; but re-examination of stored sera in the 1980s 
showed that this was not usually the case. This enteric 
form of NANBH, now termed hepatitis E, was instead 
recognized as the commonest c ~ u s e  of acute hepatitis 
in adults in India, Asia and Africa [7]. Hepatitis E virus 
(HEV) is a calicivirus-like agent. 
The classification of hepatitis viruses after HEV 
is very confused, and new candidate hepatotrophic 
viruses are still being discovered as a result of the 
application of novel molecular biological techniques. I t  
is possible that not all of these agents will definitely be 
accepted as true hepatitis viruses. A forin of sporadic 
hepatitis was described in 1991 based on examination 
of thin sections ofliver biopsies [8]. This was tentatively 
called hepatitis G, but this has Fince been dismissed. 
The infection was characterized by the presence of 
giant multinucleated syncytial hepatocytes containing 
iiitracytoplasmic structures with the appearance of 
paramyxovirus nucleocapsids. A ti0-nni particle seen in 
the livers of patients with fulminant hepatitis, a i d  in 
subsequent graft necrosis following liver transplant- 
ation, was originally proposed as hepatitis F virus. This 
may be the same as two other viruses, GBV-C and 
HGV, the R N A  of which has been found in the serum 
of multi-transfused patients by amplification of cL)NA 
fragments [9-13]. These two agents are currently 
grouped together as hepatitis G virus (HGV). Meatr- 
while the best current candidate for hepatitis F virus is 
a 27-37-nrn particle found in stool extracts by electron 
microscopy from cases of sporadic non-parentally 
acquired NANBH which are infectious for rhecu5 
monkeys by intravenous inoculation [I 41. 
The confusion that now exists in the field of 
hepatitis viruses will eventually be sorted out by the 
application of molecular bioloLy through techniques 
such as nucleic acid sequencing and by standard 
serologic methods using recombinant proteins or 
synthetic peptide antigens in surveys of the prevalence 
of antibodies to the various agents in different human 
populations. A provisional listing is given in Table 1. 
Mode of spread Size of particle (nni) Nucleic acid Family 
ss-KNA Picornaviridac Hepatitis A Feco-oral 25-30 
Hepatitis B I’.irenteral 42 ds-1lNA Hepadnaviridx 
Hepatitir C: Parenterd 
Hepat~tis E Feu-oral  27-34 sn-KNA Calicivirus-like 
Hepatitis G I’aren tcral 60 ss-RNA Flavivirus-11kc 
sq-KNA Flavivirus-like 
Hepatitis 11 Pdrenteral 35 ss-KNA ? 
Hepatitis F Feco-oral 27-37 &DNA ? 
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MULTIPLE CHOICE QUESTIONS 
In each of the numbered questions, at least one, and I A ~  tofive, 
o j  the individual entries are correct. (The answers are at the 
end qf this article.) 
1. The liver is the primary target organ for the 
(a) Hepatitis A virus True/False 
(b) Cytomegalovirus True/False 
(c) Hepatitis B virus True/False 
(d) Hepatitis C virus True/False 
(e)  Yellow fever virus True / Fals e 
following viruses 
2. Hepatitis A and B 
(a) Both have an incubation period 
ofabout 2 weeks True/False 
(b) Can both be transmitted by blood 
or blood products True/False 
(c) Cause an illness with similar 
clinical symptoms True/False 
(d) Always cause jaundice True/False 
(e)  Both cause a chronic infection True/False 
3. Acute hepatitis A 
(a) Is predominantly a disease of 
young children True/False 
(b) Is associated with poor socio- 
economic conditions True/False 
(c) In developed countries is usually 
travel associated in adults True/False 
(d) Is a significant hazard for 
healthcare workers True/False 
(e)  May be prevented by vaccination True./False 
4. Hepatitis B 
(a) Has a uniform worldwide 
carriage rate of about 10%) 
(b) May be transmitted across the 
placenta in utero 
(c) Is a sexually transmitted disease 
(d) Destroys infected hepatocytes 
by lysis 
( e )  Is the major cause of primary 
hepatocellular carcinoma 
5. Hepatitis B 
(a) Is an important cause of 
nosocomial infection 
(b) Is a preventable disease 
(c) Vaccination confers lifelong 
immunity in 99% of subjects 
(d) Immune response to vaccine 
directed against coat of virus 
True/Falte 
Trur/False 
TrudFalte 
True/Falge 
True/False 
True/False 
True/False 
TrudFalse 
TrudFalse 
(e )  May be prevented by use of 
normal human immune globulin True/False 
6. Hepatitis C 
(a) Viral R N A  is detectable in serum 
(b) Is transmitted sexually at same 
(c) Initiates a chronic infection in a 
(d) May be transmitted from mother 
(e) Can be successfully treated with 
much sooner than antibody True/False 
frequency as hepatitis B True/False 
high proportion of cases True/False 
to infant True/False 
interferon-a True/False 
7. Delta hepatitis 
(a) Virion KNA encodes for a single 
protein True/False 
(b) Virion coat is hepatitis B surface 
antigen True/ False 
(c) Viral genome resembles that of 
certain plant viruses True/False 
(d) Superinfection of a hepatitis B 
carrier leads to delta carriage True/False 
(e)  Co-infection with HBV increases 
the risk of fulnlinant disease True/ False 
8. Hepatitis E 
(a) Causes large epidemics with 
(b) Fecal contamination of drinking 
(c) Highest attack rate is in children 
(d) Is endemic in all countries of the 
(e)  Acute infection has a high 
thousands of cases True/False 
water is major source of infection True/False 
True/False 
world True/False 
mortality rate True/False 
COMMENTS 
Question 1 
Many viruses are capable of replication in hepatocytes, 
resulting in characteristic symptoms of acute infection 
of the liver, and in particular jaundice. Most viruses 
capable of systeniic infection only invade the body 
after replication in epithelial cells, and few human 
virus species are primarily hepatotrophic. HAV is an 
enterovirus in the fanlily Picornaviridae and is distantly 
related to poliovirus. The primary site of replication is 
in epithelial cells lining the gastrointestinal tract; the 
liver is infected via the bloodstream. Cytomegalovirus 
may be isolated from a variety of body fluids, including 
saliva, urine, breast milk, genital secretions and blood. 
The virus, though cytopathic, is of low pathogenicity, 
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and following acute infection the virus becomes latent 
in polyniorphonuclear leukocytes. The most common 
route of infection is by oral contact, primary virus 
replication taking place in the epithelial cells lining 
the salivary ducts. From the bloodstream the virus 
commonly infects kidneys and liver but specific 
symptoms are usually absent. During severe dissem- 
nated disease, evidence of infection may be seen in 
virtually all organs, but this is unusual. Hepatitis B and 
C viruses both replicate primarily in hepatocytes. 
There is evidence that they also replicate in peripheral 
blood lymphocytes, but is not clear how important this 
is in pathogenesis of disease [ 15,161. Yellow fever virus 
is a member of a family of viruses causing hemorrhagic 
fevers and diseases of the central nervous system; the 
majority are transmitted via biting insects. In yellow 
fever the target organ is the liver, virus replication 
causing hepatocellular damage. Renal iiivolvenient is 
coninion, with acute tubular necrosis, and there is 
considerable evidence that mononuclear leukocytes 
play an important role in the disease. 
Question 2 
Studies in priniates and humans in the 1940s and early 
1950s established the length of incubation for hepatitis 
A and B. Hepatitis A has an average incubation of 30 
days, with a range of 14 to 45 days. For hepatitis B the 
incubation period is much longer, with a mean of 70 
days and a range of 30 to 180 days. In both diseases the 
length of incubation is proportional to the dose of 
infectious virus; in particular, the extremely long 
incubation that is sometimes seen with hepatitis B niay 
reflect a small infecting dose. Hepatitis A has a viremic 
phase which precedes the appearance of jaundice. 
Although virus is present in the bloodstream for only a 
few days during this time, blood and blood products are 
capable of transmitting the infection. 
Both hepatitis A and B start with non-specific 
prodronial syniptonis including headache, malaise, 
lethargy, anorexia, nausea, vomiting and diarrhea. The 
icteric phase follows after a few days and normally lasts 
for a week or two. patients often start to feel better 
before jaundice has resolved. Some patients experience 
a serum sickness-like syndrome at the onset of the 
illness, with fever, rash and arthralgia. This is most often 
seen with hepatitis U but also occurs with hepatitis A. 
Jaundice is not universal. About 50% of HBV infections 
are anicteric, and hepatitis A is usually asymptoniatic in 
young children. Hepatitis A is generally an acute, self- 
limiting infection which is normally less severe and of 
shorter duration than hepatitis B. The mortality rate in 
otherwise fit and healthy patients is very low indeed. 
Hepatitis €3 usually has a more insidious onset and there 
are often relapses during convalescence; the mortality 
rate is about 1%. Fulniinant hepxitis, which is charac- 
terized by encephalopathy and is usually fatal, is a rare 
complication of hepatitis in developed countries; it is 
more often seen with hepatitis €3, though it can occur 
with liepatitis A. A characteristic of HBV is its ability 
to initiate a long-term carrier state in a significant 
proportion of infected patients. Chronic infection 
is unknown with HAY but rarely, in susceptible 
individuals, it can act as a trigger for autoimmune 
chronic hepatitis [17]. 
Question 3 
Hepatitis A occurs worldwide as an endemic disease. In 
developing countries there is a high incidence of 
infection. The virus is transmitted among small 
children, and most people are immune by their teem. 
In the developed countries the incidence of infection 
is falling due to improvements in public health and 
sanitation and with increasing wealth 118-201. Many 
adults in the industrialized countries have no natural 
immunity and are susceptible if they come into contact 
with a case of hepatitis A or consume contaminated 
food or water. Consequently, acute hepatitis A in adults 
from developed countries is associated with travel to 
areas of high endemicity, although infection could be 
avoided by fairly simple precautions [21]. However, 
even in a developed country such as the UK, c o n -  
niunity outbreaks of hepatitis A are common, with 
transmission by person-to-person contact [22]. 
Typically, cases of acute hepatitis are seen in older 
children and adults who are in contact with children, 
such as teachers and relatives. Food- aiid water- 
associated outbreaks have also been reported, and 
shellfish are a particularly common source of infection 
[ 23,241. Certain occupations may carry an increased 
risk of hepatitis A, e.g. sewage workers [25,26]. 
Hepatitis A is not a major hazard for healthcare 
workers; few cases of acute hepatitis A require hospital- 
ization and, since spread is feco-oral, normal hygienic 
precautions are sufficient to prevent transmission. 
A formalin-inactivated HAV vaccine prepared 
from marmoset liver was produced in 1978 and shown 
to produce protective antibody in human volunteers. 
Large-scale vaccine production became possible once 
the virus had been grown in vitro in cell culture in 
1979, although priority at that time was being given to 
HBV vaccine development. In 1986 a forinalin- 
inactivated cell-culture-grown HAV vaccine was 
shown to be safe and effective in adult human 
volunteers. Manufacturers in many countries joined in 
the development of HAV vaccines, and commercial 
vaccine became available in the UK in 1992 [27]. In 
efficacy trials, 100% seroconversion was seen in 
susceptible volunteers after two doses of vaccine given 
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2 to 4 weeks apart [28]. A third, booster dose was 
recommended after 6 months. An improved version of 
the vaccine was introduced in 1994. The primary 
course consists of a single dose with a booster dose after 
6 to 12 months for extended immunity. Most human 
isolates of HAV belong to a single serotype with less 
than 10% genotype sequence divergence, and vaccine 
should therefore give almost universal protection. 
Strains of the virus with up to 20% sequence variability 
have been isolated from different parts of the world but 
these represent only limited amino acid changes. One 
of these divergent genotypes appears to be circulating 
in a part of the world where HAV is hyperendemic, but 
the epidemiologic significance of this phenomenon is 
unknown [as]. 
Question 4 
Worldwide there may be as many as 300 million 
carriers of HBV. The carriage rate varies widely. In the 
UK, northern Europe, the USA, Canada, Australia and 
New Zealand it is 0.1% or lower, in the countries 
bordering the Mediterranean and the Middle East it is 
between 2% and 5%, whilst in sub-Saharan Africa, the 
Indian sub-continent and Central and South America 
it is between 5% and 15%. The highest rates are seen 
in the countries of South East Asia, the Far East and 
the Pacific islands, where the rate niay be as high as 20% 
of the adult population. 
In countries with a low carriage rate, higher rates 
are seen in people in aboriginal populations in ethnic 
groups originating in areas where there is a high 
carriage rate and in patients with risk factors such as a 
history of multiple transfusion, dependence upon blood 
products, immune impairment, injecting drug use and 
sexual activity with frequent partner change, partic- 
ularly sex between men. Vertical and sexual trans- 
mission are the two major routes of infection of this 
virus. Horizontal spread by exchange of body fluids 
between people who live in close physical proximity is 
also important and may explain some cases of sporadic 
hepatitis B where specific risk factors are absent. 
Intrauterine infection only occurs where there is a very 
high level of infectious virus in the bloodstream of the 
mother, as in acute infection during pregnancy and in 
a small proportion of carriers 1301. Transmission from 
mother to infant is mostly perinatal or occurs during 
the first months of life, possibly via breast milk. 
Hepatitis B viral replication does not result in lysis 
of the infected hepatocyte. Replication is intense 
during the prodromal phase of the acute illness, and this 
is accompanied by production of ‘e’ antigen and excess 
surface antigen, which are both actively secreted by the 
cell into the extracellular spaces and thence into the 
blood. The ‘e’ antigen is coded for by part of the gene 
that codes for the core protein of the virus, which has 
two promoter sites. Core antigen is not secreted by the 
cell and is not found in the blood other than as a 
component of mature virus particles; antibody to the 
core, initially IgM and later IgG, is consistently detected 
in acute cases, carriers and those who have recovered 
from the infection. During the normal course of the 
disease, viral replication falls off and ‘e’ antigen is 
replaced in the blood by its corresponding antibody. 
Ultimately all replication may cease, surface antigen 
disappear and, after a very variable time interval, 
antibody to surface antigen become detectable. Most 
carriers have only low levels of viral replication, 
characterized by the presence of ‘e’ antibody in blood, 
but not antibody to surface antigen (anti-HBs). It has 
been suggested that clearance of infected hepatocytes 
from the liver is a function of a cell-mediated immune 
response to viral nucleocapsid and surface proteins. 
High serum levels of the cytokines tumor necrosis 
factor and interleukin-2 and -6 have been observed in 
the prodromal phase of acute infection and they may 
have a role in hepatocyte injury [31]. Chronic carriage 
develops in approximately 70% of neonates and very 
young children, in whom the immune response is 
immature, and in adults who are immunosuppressed. 
Five per cent or fewer of acutely infected healthy adults 
become carriers and symptoniatic infection rarely 
results in carriage. I t  has been concluded that establish- 
ment ofthe carrier state is the result of an impaired cell- 
mediated response. Possible mechanisms include failure 
of the major histocompatibility complex to invoke a 
response and an absence of endogenous interferon 
production [32]. The protein product of the viral X 
gene, which is now thought to function as a 
transcriptional transactivation protein, may play a 
determining part in the range of pathogenesis of HBV 
infection, from fulminant hepatitis to asymptomatic 
carriage [33]. 
The consequence of chronic infection is often 
chronic liver disease [34], and the viral genome may 
become integrated into the host-cell genome, ulti- 
mately leading to primary hepatocellular carcinoma 
(HCC). The probability that a carrier of HBV will 
develop hepatocellular cancer is 1 00-fold greater than 
for non-infected individuals, and regions with high 
rates of carriage have the highest incidence of HCC. 
Question 5 
Before the advent of screening for HBsAg, hepatitis B 
was a frequent and sometimes serious complication of 
blood transfusion, treatment with blood products, 
hemodialysis and organ transplantation. There are still 
a few cases of post-transfusion hepatitis B each year 
because a screening assay has failed to detect surface 
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antigen in a patient who has infectious virus in their 
blood. 
In some cases of hospital-acquired infection the 
patient is infected during surgery or some other 
invasive procedure from a healthcare worker, usually a 
surgeon, who is a carrier of HBV [35-381. The UK 
guidelines stipulate that all healthcare workers involved 
in exposure-prone procedures where there is a possi- 
bility of transmission of HBV should be vaccinated. 
Those who fail to respond after three doses and a 
booster should be tested for other HBV markers. 
Anyone who is HBV surface antigen positive should be 
tested for ‘e’ antigen and antibody, and if they are ‘e’ 
antigen positive should not be permitted to perform 
exposure-prone procedures [39,40J. 
A small percentage of carriers have a precore stop 
mutation in the gene coding for the core protein of the 
virus. The effect of this mutation is to prevent transla- 
tion of the protein, and ‘e’ antigen is not secreted into 
the blood even where there is a high level of virus 
replication 141,421. These rare carriers may also 
transmit HBV Another nosocomial source of HBV is 
cross-infection between patients. 
Perinatal infection can be prevented by immune 
prophylaxis with hyperimmune immunoglobulin and 
vaccine at birth. This will significantly reduce the 
number of carriers in the coinniunity in the future and 
is the most effective way to reduce the morbidity and 
mortality that result from HBV infection [43-461. In 
countries where there is a very low prevalence of HBV, 
e.g. the UK, screening of pregnant women for HBsAg 
and prophylaxis for their infants is the single most 
effective intervention to prevent hepatitis B. 
All HBV vaccines consist of surface antigen 
proteins. The first vaccines were prepared from human 
plasma, treated to inactivate infectious virus. Second 
generation vaccines were recombinant proteins made 
bylcloning and expressing the surface antigen gene, in 
yeast in the case ofEngerix B. These vaccines contained 
only the S epitope of the surface antigen protein, 
whereas the plasma-derived vaccines had also contained 
the pre-S1 and pre-S2 epitopes. New recombinant vac- 
cines are in development with all epitopes represented. 
Clinical trials of vaccine were carried out in 
healthy young adult volunteers and levels of greater 
than 10 IU/L were seen in almost 100% following three 
doses of vaccine. Very little difference was seen between 
the plasma-derived and recombinant vaccines. Because 
of the diversity of individual responses to vaccine, the 
time-dependent decrease in antibody level seen in all 
studies and the possibility of errors in quantitative 
antibody determination, it was recommended that 
patients with a level less than 100 IU/L should be 
boosted. The UK policy is to give further booster doses 
after 5 years or earlier if the level of antibody is found 
to have fallen below 100 IU/L. In the USA it is 
assunied that the immune memory is adequate for 
long-term protection, even where the level of circul- 
ating antibody has fallen below 10 IU/L [47]. There 
are few studies on the persistence of long-term 
immunologic memory with recombinant vaccines; in 
one in vitro study, immunologic memory for HBsAg 
was seen in B-lymphocytes derived from vaccinees 
who had lost their antibody but not in B-cells from 
non-responders [48]. Vaccine response declines with 
age and is better in women than in men 1491. 
Our experience in nearly 6000 healthcare workers, 
tested within 2 months of completion of a course of 
three doses, was that 8% had less than 10 IU/L and a 
further 13%) between 10 and 100 IU/L anti-HBs. In 420 
subjects given a booster because they had less than 100 
IU/L after three doses and where all antibody tests were 
performed within 2 months after vaccination, we found 
that 25% had less than 10 IU/L and 42%) more than 100 
IU/L after the fourth dose; 56% of those with lcsc than 
10 IU/L after three doses still had less than 10 IU/L after 
four doses. A proportion of vaccine non-responders are 
chronic carriers or have serologic evidence of past 
infection; it has also been suggested that non- 
responsiveness might be due to latent infection [SO]. 
Normal human irnniunoglobulin made from 
donated blood in industrialized countries contains only 
low levels of antibody to HBV In the UK, specific 
hyperininiune immunoglobulin is prepared from the 
plasma of donors with high levels of anti-HBs, and 
preparations typically contain 100,000 IU/L. Human 
anti-HB monoclonal antibodies manufactured in 
transformed human mononuclear cells niight be used 
in the future for passive prophylaxis [51]. Before the 
advent of HBV vaccine, anti-HI3 immunoglobulin was 
used for prophylaxis following exposure to HBV and 
for treatment of the infants of HBsAg-positive mothers; 
two doses were necessary at  an interval of 1 month. I n  
babies a third dose was often given at 6 months. It  is 
now used in combination with vaccine for prophylaxis 
of non-vaccinated personnel and vaccine non- 
responders who have been exposed to a known HBV- 
positive person, and for infants of ‘e’ antigen-positive 
mothers; only a single dose is necessary. Long-term 
immune prophylaxis of HBsAg-positive patients with 
cirrhosis or fulminant hepatitis who undergo liver 
transplantation has been found to reduce the incidence 
of reinfection of the graft [52]. 
Question 6 
Acute hepatitis C is often asymptomatic and sporadic 
cases are rarely diagnosed at the time of infection. Much 
that is known about the disease has been learned from 
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studies of post-transfusion jaundice, although there is no 
significant difference between this and the sporadic 
disease. Specific antibody response is delayed for several 
weeks following exposure to the virus, but viremia is 
detectable much sooner, as shown by a positive 
polymerase chain reaction (PCR) following extraction 
and reverse transcription of viral R N A  to cDNA. 
Studies of both post-transfusion and sporadic 
hepatitis C have shown that the patient brcomes 
chronically infected in more than 50% of cases [53]. 
There is some evidence that antibody levels remain 
high in patients with chronic infection but fall with 
time in those who clear the virus. Chronic infection is 
associated with raised though often fluctuating serum 
transaminase levels. Examination of liver biopsies 
reveals histopathologic evidence of chronic liver 
disease, and cirrhosis is a long-term consequence, 
though the rate of progression is usually very slow 
[54-561. There is evidence that HCV has an etiologic 
role in mixed cryoglobulinemia, HCV RNA being 
detected in peripheral blood mononuclear cells and 
bone marrow cells [57]. 
Transfusion with blood or treatment with blood 
products are major risk factors for hepatitis C, and 
seroprevalence of HCV antibodies is high in multiply- 
transfused patients and hemophiliacs [58,59]. Studies of 
sporadic hepatitis C and seroprevalence studies in risk 
groups point to injecting drug use as a major risk. factor. 
Our own studies in patients attending genitourinary 
medicine clinics in the UK show an HCV antibody 
seroprevalence of 58% in injecting drug users compared 
to 2.8% in homosexual men and 0.7% in subjects of 
both sexes with multiple sexual partners. Serologic 
studies of sexually promiscuous groups show that the 
rate of seropositivity is significantly higher than in 
controls, indicating some sexual transmission, but at 
much lower frequency than with hepatitis B [60-651. 
One study in hemophiliacs failed to show an); sexual 
transmission but noted that this cohort might be more 
likely than others to practice protected intercourse to 
avoid HIV transmission 1661. In another study the 
chance of being HCV positive was three times higher 
in the sexual partners of patients with chronic hepatitis 
than in those whose HCV-infected partners had no 
biochemical evidence of liver disease and five times 
higher than in controls [67]. 
The evidence for vertical transmission of HCV 
from mother to infant is far from conclusive. Some 
recent studies of anti-HCV in mother-and-infant pairs 
have failed to demonstrate persistence of passively 
acquired antibohes even in the infants of HIV-positive 
mothers [68]. In contrast, in a study using nested PCR,  
viremia was found in five out of eight HIV-positive 
women and in four of their offspring [69]. One  child 
had persistent viremia, chronic elevation of trans- 
aminases and remained anti-HCV positive; the other 
three children had intermittent vii-emia but lost their 
HCV antibodies. Lack of persistence of anti-HCV in 
the child is possibly insufficient evidence from which 
to conclude that vertical transmission has not occurred. 
Interferon-a is increasingly being used to treat 
patients with chronic HCV infection, inducing 
remission in up to 50% of patients [70,71]. The 
response is inversely correlated with pretreatment 
serum levels of HCV R N A  and severity of liver disease, 
and is influenced by HCV genotype [72]. It has been 
suggested that interferon selects resistant subtypes of the 
virus which replicate once treatment is withdrawn [73]. 
Measurable persistence of HCV R N A  in serum is a 
better indicator of response to interferon than the 
serum transaminase levels. 
Question 7 
HDV is a unique animal virus and bears a striking 
resemblance to a number of plant pathogens known as 
viroids [74]. The HDV R N A  is a single-stranded 
circular molecule, approximately 1700 nucleotides long, 
with an unbranched rod-shaped secondary configur- 
ation caused by pairing of up to 70% of the bases. 
Complementary antigenomic R N A  is detected in 
infected hepatocytes, serving as a template for synthesis 
of progeny R N A  genomes. The largest open reading 
frame of the antigenomic R N A  codes for the single 
viral-encoded protein, delta antigen. In the maturing 
virion, the R N A  genome is encapsulated in the delta 
antigen, which is then enclosed in a coat of surface 
antigen provided by the helper HBV. 
Fulminant hepatitis is seen significantly more often 
in co-infected patients than in those infected with HBV 
alone, especially when infection with HBV and HDV 
is simultaneous. Serum HBV DNA and HBsAg levels 
are lower, suggesting that HDV suppresses HBV 
replication. Chronic carriage is rare following simul- 
taneous infection, but when it occurs progression to 
chronic liver disease is much more rapid than with 
HBV carriage alone. Acute hepatitis is seen in 50% to 
70% of HBV carriers who are superinfected with HDV. 
Persistent levels of IgM antibody to delta antigen 
following superinfection, which are not seen with co- 
infection, are evidence of ongoing replication of HDV, 
with the possibility of more rapid progression to 
chronic active hepatitis and cirrhosis. 
Question 8 
In developing countries the majority of the population 
have been infected with HAV in early childhood, 
chiefly by close personal contact with an infectious 
case and usually in the absence of symptoms. Large 
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outbreaks of hepatitis with thousands of cases have been 
described in South East Asia, Africa, Mexico, Central 
America, the Indian subcontinent, China and the 
former USSK. These cases were predominantly in 
adults between the ages of 15 and 40, and fecal 
contamination of water was identified as the vehicle of 
transmission. Serologic studies of patients in these 
outbreaks showed that most were already immune to 
HAV and that the etiologic agent was a recently 
described virus, HEV. The first well-documented 
outbreak of HEV was in New Delhi in 1955 where 
flood contamination of a drinking water supply 
apparently led to many thousands of cases of jaundice. 
A conimercial immunoassay for IgG and IgM 
antibodies to HEV was developed in 1992, and virus 
particles have been described based on electron 
microscopic examination of stool samples from infected 
patients 1751. The virus has also been propagated in cell 
culture and shown to be neutralized by patients’ sera 
[76]. The inorphologic and biophysical properties of 
the virus are similar to those of caliciviruses. IgG 
antibody persists at a reduced titer after recovery from 
the acute illness and appears to be protective. Where 
reinfection occurs it does not commonly cause serious 
illness and may be subclinical [77]. Acute hepatitis E is 
normally a self-limiting illness with features similar to 
hepatitis A, and a full recovery. The exception is in 
pregnant women, where mortality rates as high as 20% 
have been recorded [78]. 
Answers to the multiple choice questions 
Q1: a. False; b. False; c. True; d. True; 
Q2: a. False; b. True; c. True; d. False; 
Q3: a. True; b. True; c. False; d. False; 
Q4: a. False; b. True; c. True; d. False; 
Q5: a. True; b. True. c. False; d. True; 
Q6: a. True; b. False; c. True; d. True; 
Q7: a. True; b. True; c. True; d. True; 
Q8: a. True; b. True; c. False; d. False; 
e. True 
e. False 
e. True 
e. True 
e. False 
e. True 
e. True 
e. False 
Further reading 
For historical background the British Medical Bulletin 
1972, volume 28, number 2, is invaluable. This issue 
was devoted to viral hepatitis and was written just as the 
prospect of widespread testing for markers of hepatitis 
infection was starting to become a reality. Prof. A. J. 
Zuckerinan’s book, Human Viral Hepatitis, published 
by the North-Holland Publishing Company of 
Amsterdam and Oxford (ISBN 0-7204-45132) and the 
Aiiierican Elsevier Publishing Co., Inc. of New York 
(ISBN 0-444-10849-1) (Library of Congress Catalog 
No. 72-86770), contains much valuable information, 
including detailed clinical and pathologic descriptions 
of the disease. The Proceedings of the 1984 Inter- 
national Symposium on Viral Hepatitis entitled Viral 
Hepatitis and Liver Disease, published by Grune and 
Stratton, Inc. (ISBN 0-8089-1 678-5) (Library of 
Congress Catalog No. 84-08 1469), is particularly 
useful for the sections on prophylaxis and control of 
hepatitis. The proceedings of an international sym- 
posiuni on Prospects for control of hepatitis B organized 
by SmithKline Biologicals, manufacturers of the first 
yeast-derived recombinant DNA vaccine, were pub- 
lished in the Postgraduate Medical Journal 1987, volume 
63, supplenient 2. These proceedings contain details 
of many of the vaccine trials with the recornbinant 
hepatitis B vaccine. The proceedings of a workshop on 
HAV vaccine held in February 1994 on Marco Island, 
Florida were published in the journal cf lnfectiocis 
Diseases 1995, volume 171, supplement 1 ,  under the 
title ‘An overview of the clinical development of 
hepatitis A vaccine’. Finally, the Wellconie Foundation 
Ltd in association with Pennine Press published a book 
in 1990 entitled Interferons in the 3eatrncnt of Clwonir 
Virus Infection o f t h e  Liver (ISBN 1-870665-30-9) by A. 
L. E Eddleston and B. Dixon. 
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